– USA, MA – KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, today announced the appointment of Mahesh Karande to its board of directors.
“Mahesh’s deep experience in company leading, product commercialization, fundraising, and deal-making are great additions to the skillset we’ve assembled on our board. His insights and guidance will be invaluable as we continue to advance KSQ-4279 through clinical studies and work towards bringing our engineered TIL cell therapy programs into the clinic,” said CEO, Qasim Rizvi.
About Mahesh Karande
Mahesh Karande is the President and CEO of Omega Therapeutics (Nasdaq: OMGA), a clinical-stage biotechnology company pioneering Omega Epigenomic Controllers, a new class of programmable mRNA medicines. At Omega, he has led the company’s development of its Epigenomic Programming platform and the translation of novel science into a broad pipeline in oncology, regenerative medicine, immunology, inflammatory conditions, and important monogenic conditions. Before Omega, he was CEO of Macrolide Pharma, where he re-assessed the company’s core strategy and optimized a path forward for the highest shareholder return. Mahesh previously held numerous leadership roles at Novartis Pharmaceuticals, most recently as a corporate-level VP and US franchise Head leading the oncology solid tumors business. He also served as President of Africa, President of Egypt, and Regional VP of strategy and business development for emerging markets, where he oversaw the execution of more than 50 partnership deals. He has led more than 10 product launches in the U.S. and across global markets. Before entering the pharmaceutical industry, Mahesh worked for the global management consulting firm McKinsey.
“KSQ’s platform and science are impressive and have yielded multiple exciting and novel targets that provide significant opportunities to help patients with various cancers and solid tumors,” said Mahesh Karande. “I look forward to working closely with the company to maximize the potential of its programs, including KSQ-4279 and the eTIL cell therapy franchise, and I’m excited to see where the CRISPRomics platform can take us as we move into new and exciting areas, including NK cells, Tregs and myeloid cells.”
Mahesh has an M.B.A. from the Wharton School, University of Pennsylvania. He is also a graduate of the Georgia Institute of Technology, where he completed his M.S. in engineering, and the University of Bombay, where he completed undergraduate studies in engineering.
About KSQ Therapeutics
KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer and autoimmune disease across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ’s proprietary CRISPRomics discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas.
For more information: https://ksqtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
